Posted Mar. 11, 2013 at 6:51 a.m.
Research Triangle Park, N.C. — Novozymes technology promises to increase the active life of the new diabetes drug, meaning type 2 diabetes sufferers could inject once a week instead of daily. Novozymes uses genetically modified proteins that allow GSK to fuse its drug with albumin found in blood serum, fooling the body into accepting the active ingredients that it would normally deem foreign and expel.Copyright 2013 WRAL Tech Wire. All rights reserved.
GSK diabetes drug could deliver big dividend for Novozymes
Post a comment
Print this blog postE-mail blog post
Share
Research Triangle Park, N.C. — Novozymes technology promises to increase the active life of the new diabetes drug, meaning type 2 diabetes sufferers could inject once a week instead of daily. Novozymes uses genetically modified proteins that allow GSK to fuse its drug with albumin found in blood serum, fooling the body into accepting the active ingredients that it would normally deem foreign and expel.Copyright 2013 WRAL Tech Wire. All rights reserved.
Please Log In to add a comment.
Best of TechWire Insider
The Skinny
Durham's high-tech infrastructure, talent lure Virginia company
Lenovo acknowledges layoffs in Morrisville as part of shift to 'PC Plus' strategy
Raleigh-based PRA International eyes public offering
Will lightning strike again for veteran entrepreneur Brian Handly at StepLeader?
Raleigh app developer StepLeader lands $4.4M in first fund raiser
IBM opens Linux center in China, says it will work with Red Hat
Red-hot Raleigh startup WedPics hauls in $1.1M in funding
New Triangle venture capital firm slowly emerging from shadows
Titans of tech seek to excite UNC, Duke grads about a future beyond themselves
Triangle politician tries to accelerate crowdfunding; bill passes first hurdle















